Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. HYPR
HYPR logo

HYPR Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
1.096
Open
1.070
VWAP
1.08
Vol
124.70K
Mkt Cap
100.90M
Low
1.060
Amount
134.93K
EV/EBITDA(TTM)
--
Total Shares
97.96M
EV
65.81M
EV/OCF(TTM)
--
P/S(TTM)
6.21
Hyperfine, Inc. is a health technology company. The Company is engaged in providing patient care globally through artificial intelligence (AI)-powered portable ultra-low-field (ULF) magnetic resonance (MR) brain imaging. Its Swoop Portable MR Imaging System (Swoop system) produces images at a lower magnetic field strength than conventional magnetic resonance imaging (MRI) scanners. Its Swoop system is designed to transform brain MR for the patient, the clinician and the provider, enabling a highly differentiated experience for patients, timely imaging for clinicians, and favorable economics for hospital administrators. The Swoop system is a portable ULF MRI device for producing images that display the internal structures of the head where full diagnostic examination is not clinically practical. The Swoop system is FDA-cleared for brain imaging of patients of all ages. The Swoop system is commercially available in a select number of international markets.
Show More

Events Timeline

(ET)
2026-03-23
08:10:00
Horizon Technology Provides $40M Loan to Hyperfine
select
2026-03-18 (ET)
2026-03-18
16:10:00
Hyperfine Reports Q4 Revenue of $5.29M
select
2026-01-20 (ET)
2026-01-20
08:20:00
Hyperfine Announces NEURO PMR Study Results, Portable MRI Shows Superiority
select
2026-01-15 (ET)
2026-01-15
08:20:00
Hyperfine Enrolls First Patient in Contrast PMR Study
select
2026-01-12 (ET)
2026-01-12
08:40:00
Hyperfine Reports FY25 Revenue of $13.5M
select
2025-12-17 (ET)
2025-12-17
08:40:00
Hyperfine's Swoop System Receives Regulatory Approval in India
select
2025-12-15 (ET)
2025-12-15
08:30:00
Hyperfine Receives FDA Clearance for New Imaging Software
select

News

PRnewswire
7.5
03-27PRnewswire
Heart Disease Crisis Fuels AI Diagnostic Platforms
  • Economic Burden of Heart Disease: Heart disease costs the European Union over €282 billion annually and claims 1.7 million lives, driving institutional capital to rapidly invest in scalable AI diagnostic platforms, highlighting the urgent market demand for innovative healthcare solutions.
  • Growth of AI Medical Devices: The FDA has approved over 1,200 AI medical devices, with cardiovascular applications emerging as the second largest category, indicating a strong alignment between regulatory support and clinical needs, providing a favorable environment for AI-driven medical technologies.
  • Remote Healthcare Collaboration: VentriPoint Diagnostics is partnering with First Light Health to deliver AI cardiac diagnostics in remote Canadian communities, utilizing the VMS+™ system to enable local providers to collaborate with central specialists, significantly enhancing healthcare accessibility in underserved areas.
  • Potential for Technological Expansion: VentriPoint's VMS+™ system converts standard 2D echocardiograms into 3D volumetric images with accuracy comparable to cardiac MRI, which is expected to drive widespread adoption in underserved communities globally, addressing critical gaps in heart disease diagnosis.
Newsfilter
7.5
03-27Newsfilter
Heart Disease Crisis Fuels AI Diagnostic Platforms
  • Economic Burden of Heart Disease: Heart disease costs the European Union over €282 billion annually and claims 1.7 million lives each year, driving institutional capital towards scalable AI diagnostic platforms, highlighting the urgent market demand for innovative healthcare solutions.
  • Growth in AI Medical Device Registrations: The FDA has approved over 1,200 AI medical devices, with cardiovascular applications emerging as the second-largest category, providing a robust regulatory foundation that supports the rapid growth of companies in this sector.
  • Remote Healthcare Collaboration: VentriPoint Diagnostics has partnered with First Light Health to deliver AI-powered cardiac diagnostics to Indigenous and remote communities in Canada, utilizing the VMS+™ system to enhance accessibility and efficiency in healthcare delivery.
  • Technological Innovation and Market Expansion: VentriPoint's VMS+™ system converts standard 2D echocardiograms into 3D volumetric images with MRI-level accuracy at a lower cost, positioning the company to expand into underserved global communities and address significant gaps in heart disease diagnosis.
Yahoo Finance
8.5
03-24Yahoo Finance
Hyperfine Secures $40M Loan for Swoop System Expansion
  • Funding Support: Hyperfine has secured a $40 million loan from Horizon Technology, with an initial $15 million available at closing and up to $25 million for future commercial initiatives, significantly enhancing the market competitiveness of its Swoop system.
  • Technological Innovation: The Swoop system, which has received FDA clearance, offers AI-powered point-of-care brain imaging in various settings such as ICUs, emergency departments, and smaller community hospitals, thereby improving accessibility to medical services.
  • Market Outlook: Horizon's Chief Investment Officer Paul Seitz noted that Hyperfine's technology platform expands access to brain imaging in environments where conventional MRI is not feasible, showcasing strong clinical and economic evidence that indicates a broad commercial opportunity.
  • Global Expansion Plans: Hyperfine CEO Maria Sainz stated that this financing will accelerate the commercial expansion of the Swoop system across hospitals and clinics, aiming to provide high clinical and economic value MRI services for acute and chronic brain conditions.
moomoo
8.5
03-23moomoo
Horizon Grants $40 Million Loan Facility to Hyperfine, with $15 Million Disbursed at Closing
  • Loan Facility Announcement: Hyperfine Inc. has secured a $40 million loan facility to support its operations and growth.

  • Funding Details: The loan is backed by a $15 million funding commitment that was finalized at closing.

NASDAQ.COM
2.0
03-19NASDAQ.COM
Hyperfine (HYPR) Q4 2025 Earnings Call Transcript
Yahoo Finance
9.5
03-19Yahoo Finance
Hyperfine Inc Reports Strong Q4 Earnings with Significant Growth
  • Significant Revenue Growth: Hyperfine Inc reported Q4 2025 revenue of $5.3 million, a 128% increase from the previous year, demonstrating strong performance in the next-generation Swoop scanner market and indicating potential for future sales growth.
  • Gross Margin Expansion: The company achieved a gross margin of 50.9% in Q4, representing a 1,530 basis point increase year-over-year, highlighting successful cost control and pricing strategies that enhance its competitive position in the market.
  • Reduced Cash Burn: Net cash burn for Q4 2025 was $5.7 million, down 30% year-over-year, reflecting improved financial discipline and operational efficiency, which is likely to boost investor confidence.
  • Optimistic 2026 Outlook: Hyperfine anticipates 2026 revenue between $20 million and $22 million, representing a 55% growth at the midpoint, with gross margin guidance set at 50% to 55%, indicating a positive outlook on future market opportunities.
Wall Street analysts forecast HYPR stock price to rise
1 Analyst Rating
Wall Street analysts forecast HYPR stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
2.00
Averages
2.00
High
2.00
Current: 0.000
sliders
Low
2.00
Averages
2.00
High
2.00
Lake Street
Buy
maintain
$2
AI Analysis
2026-03-19
Reason
Lake Street
Price Target
$2
AI Analysis
2026-03-19
maintain
Buy
Reason
Lake Street raised the firm's price target on Hyperfine to $2.50 from $2 and keeps a Buy rating on the shares. Q4 "marked a step-function in system placements, and we think represents an inflection to Hyperfine 2.0," the analyst tells investors following the company's quarterly report.
B. Riley
NULL -> Buy
upgrade
2026-03-19
Reason
B. Riley
Price Target
2026-03-19
upgrade
NULL -> Buy
Reason
B. Riley raised the firm's price target on Hyperfine to $1.60 from $1.30 and keeps a Buy rating on the shares. Hyperfine's Q4 revenue was slightly above estimates, driven by 16 unit placements including a one-time multi-unit upgrade at a health system, and FY26 guidance of $20M-$22M exceeds Street expectations, with gross margins of 50%-55% and cash burn of $26M-$28M, supported by multi-unit IDN deals, neurology office expansion leveraging NEURO-PMR data, and a 2H26 international launch of the next-gen Swoop, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for HYPR
Unlock Now

Valuation Metrics

The current forward P/E ratio for Hyperfine Inc (HYPR.O) is -2.77, compared to its 5-year average forward P/E of -1.89. For a more detailed relative valuation and DCF analysis to assess Hyperfine Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.89
Current PE
-2.77
Overvalued PE
-0.68
Undervalued PE
-3.10

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.64
Current EV/EBITDA
-2.44
Overvalued EV/EBITDA
1.19
Undervalued EV/EBITDA
-2.47

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
7.28
Current PS
5.64
Overvalued PS
15.94
Undervalued PS
-1.37

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

take me to stock radar
Intellectia · 53 candidates
Region: USPrice: $1.00 - $30.00Volume: >= 1,000,000Price Change Pct: $-25.00 - $25.00Relative Vol: >= 2List Exchange: XNYS, XNAS
Ticker
Name
Market Cap$
top bottom
SATL logo
SATL
Satellogic Inc
729.00M
HUYA logo
HUYA
HUYA Inc
1.01B
GNTA logo
GNTA
Genenta Science SPA
30.70M
ATOM logo
ATOM
Atomera Inc
105.50M
BAER logo
BAER
Bridger Aerospace Group Holdings Inc
173.85M
UROY logo
UROY
Uranium Royalty Corp
683.86M

Whales Holding HYPR

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Hyperfine Inc (HYPR) stock price today?

The current price of HYPR is 1.09 USD — it has increased 5.83

What is Hyperfine Inc (HYPR)'s business?

Hyperfine, Inc. is a health technology company. The Company is engaged in providing patient care globally through artificial intelligence (AI)-powered portable ultra-low-field (ULF) magnetic resonance (MR) brain imaging. Its Swoop Portable MR Imaging System (Swoop system) produces images at a lower magnetic field strength than conventional magnetic resonance imaging (MRI) scanners. Its Swoop system is designed to transform brain MR for the patient, the clinician and the provider, enabling a highly differentiated experience for patients, timely imaging for clinicians, and favorable economics for hospital administrators. The Swoop system is a portable ULF MRI device for producing images that display the internal structures of the head where full diagnostic examination is not clinically practical. The Swoop system is FDA-cleared for brain imaging of patients of all ages. The Swoop system is commercially available in a select number of international markets.

What is the price predicton of HYPR Stock?

Wall Street analysts forecast HYPR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HYPR is2.00 USD with a low forecast of 2.00 USD and a high forecast of 2.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Hyperfine Inc (HYPR)'s revenue for the last quarter?

Hyperfine Inc revenue for the last quarter amounts to 5.29M USD, increased 128.05

What is Hyperfine Inc (HYPR)'s earnings per share (EPS) for the last quarter?

Hyperfine Inc. EPS for the last quarter amounts to -0.06 USD, decreased -57.14

How many employees does Hyperfine Inc (HYPR). have?

Hyperfine Inc (HYPR) has 102 emplpoyees as of March 31 2026.

What is Hyperfine Inc (HYPR) market cap?

Today HYPR has the market capitalization of 100.90M USD.